Symbol="ATOS"
AssetType="Common Stock"
Name="Atossa Genetics Inc"
Description="Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered in Seattle, Washington."
CIK="1488039"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="SURGICAL & MEDICAL INSTRUMENTS & APPARATUS"
Address="2345 EASTLAKE AVENUE EAST, SUITE 201, SEATTLE, WA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="151949000"
EBITDA="-30033000"
PERatio="None"
PEGRatio="0"
BookValue="0.89"
DividendPerShare="0"
DividendYield="0"
EPS="-0.24"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.148"
ReturnOnEquityTTM="-0.229"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.24"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="4.63"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.627"
EVToRevenue="-"
EVToEBITDA="2.557"
Beta="1.169"
num_52WeekHigh="1.39"
num_52WeekLow="0.5"
num_50DayMovingAverage="0.848"
num_200DayMovingAverage="0.782"
SharesOutstanding="126624000"
DividendDate="2018-04-20"
ExDividendDate="None"
symbol="ATOS"
open="1.21"
high="1.23"
low="1.16"
price="1.23"
volume="1105251.00"
latest_trading_day="2023-07-06"
previous_close="1.20"
change="0.03"
change_percent="2.5000%"
aroon_positive_momentum_days="66"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Buy Signal"
volume_analysis="Trending Low"
value_analysis="Bearish Trend"
Aroon_change="FALSE"
Aroon_momentum="66"
Volume_recent_avg="606378"
Change_recent_avg="0.01"
Delta_recent_avg="0.06"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-0.12"
RSI_change="FALSE"
ADX_change="FALSE"

event="aroon_milestone_positive_30"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="66"
Aroon_momentum_negative="34"
image_negative_thumbnail_id_1="514"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0091.jpeg"
image_negative_thumbnail_id_2="143"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0033.jpeg"
image_neutral_thumbnail_id_1="578"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0021.jpeg"
image_neutral_thumbnail_id_2="521"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0078.jpeg"
image_positive_thumbnail_id_1="690"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0018.jpeg"
image_positive_thumbnail_id_2="702"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0006.jpeg"
image_professor_thumbnail_id_1="1189"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0023.jpeg"
image_professor_thumbnail_id_2="1191"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0025.jpeg"
